HeartSciences Granted U.S Patent for ECG Assessment of Heart Diastolic Function Using Artificial Intelligence
Southlake, Texas, Sept. 20, 2022 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ:HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on applying innovative AI-based technology to an ECG (also known as an EKG) to significantly expand and improve an ECG’s clinical usefulness by detecting cardiac dysfunction, today announced that it has been granted a patent from the United States Patent and Trademark Office (USPTO) for ECG quantification of echocardiographic measures of diastolic function of the heart using AI methods.
Related news for (HSCS)
- HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
- Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
- HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
- HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
- HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 – Featuring CEO Andrew Simpson